Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Xencor, Inc. (NASDAQ:XNCR) has earned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $24.8750.

Several research firms have commented on XNCR. Barclays lifted their target price on shares of Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. dropped their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Royal Bank Of Canada upped their price objective on Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Wedbush reiterated an “outperform” rating and set a $26.00 target price on shares of Xencor in a research note on Thursday, November 6th.

Xencor Price Performance

NASDAQ XNCR opened at $12.79 on Monday. Xencor has a 1 year low of $6.92 and a 1 year high of $21.00. The firm has a market cap of $913.33 million, a price-to-earnings ratio of -7.23 and a beta of 0.97. The company has a fifty day moving average price of $15.62 and a 200-day moving average price of $12.08.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.64. Xencor had a negative net margin of 87.14% and a negative return on equity of 20.44%. The company had revenue of $21.00 million for the quarter, compared to analyst estimates of $29.73 million. During the same period last year, the firm earned ($0.71) earnings per share. The firm’s revenue was up 18.0% on a year-over-year basis. On average, research analysts anticipate that Xencor will post -3.68 EPS for the current fiscal year.

Insider Activity

In related news, VP John R. Desjarlais sold 73,367 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $15.72, for a total value of $1,153,329.24. Following the transaction, the vice president owned 236,574 shares in the company, valued at approximately $3,718,943.28. This represents a 23.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $15.71, for a total value of $1,796,862.67. Following the transaction, the chief executive officer directly owned 466,635 shares of the company’s stock, valued at approximately $7,330,835.85. This trade represents a 19.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 4.76% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in XNCR. Hantz Financial Services Inc. increased its holdings in Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 2,156 shares during the last quarter. GAMMA Investing LLC boosted its position in Xencor by 77.1% during the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 1,449 shares during the period. Farther Finance Advisors LLC bought a new position in Xencor during the third quarter worth about $44,000. Tower Research Capital LLC TRC increased its stake in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 3,018 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Xencor by 114.3% in the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 2,105 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.